Azenosertib (ZN-c3)
Cyclin E1+ Platinum-Resistant Ovarian Cancer (PROC)
Key Facts
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecule therapeutics for cancer. Its primary achievement is the advancement of azenosertib, a potentially best-in-class WEE1 inhibitor, which has secured FDA Fast Track designation for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company's strategy is biomarker-driven, focusing initially on this high-need PROC population while exploring broader combination potential across multiple tumor types to maximize the asset's franchise value.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecule therapeutics for cancer. Its primary achievement is the advancement of azenosertib, a potentially best-in-class WEE1 inhibitor, which has secured FDA Fast Track designation for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company's strategy is biomarker-driven, focusing initially on this high-need PROC population while exploring broader combination potential across multiple tumor types to maximize the asset's franchise value.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecule therapeutics for cancer. Its primary achievement is the advancement of azenosertib, a potentially best-in-class WEE1 inhibitor, which has secured FDA Fast Track designation for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company's strategy is biomarker-driven, focusing initially on this high-need PROC population while exploring broader combination potential across multiple tumor types to maximize the asset's franchise value.
View full company profileAbout Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecule therapeutics for cancer. Its primary achievement is the advancement of azenosertib, a potentially best-in-class WEE1 inhibitor, which has secured FDA Fast Track designation for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company's strategy is biomarker-driven, focusing initially on this high-need PROC population while exploring broader combination potential across multiple tumor types to maximize the asset's franchise value.
View full company profile